Stem Cell Therapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Cell Source (Adult Stem Cells, Hematopoietic Stem Cells, Mesenchymal Stem Cells, Human Embryonic Stem Cells, and Induced Pluripotent Stem Cells), By Type (Allogeneic Transplants and Autologous Transplants), By Application (Musculoskeletal Disorders, Inflammatory & Autoimmune Disease, Oncology, Cardiovascular Diseases, Wounds and Injuries, Haematology, Neurological Disorders, and Other Application), By End User (Hospitals & Specialty Clinics, Pharmaceutical and Biotechnology Companies, and Academic & Research Institutes,) and Region Forecast 2020-2031

Stem Cell Therapy Market size was valued at US$ 307.7 million in 2024 and is projected to reach US$ 828.5 million by 2031 at a CAGR of 15.2% from 2025-2031. Moreover, the U.S. Stem Cell Therapy Market is projected to grow significantly, reaching an estimated value of US$ 258.5 Million by 2031. Stem cell therapy is a certain type of regenerative medicine that deals with the process of transplanting human stem cells to restore or establish the normal function of tissues.

The market is experiencing robust growth, driven primarily by increased research funding and supportive government initiatives. These financial inflows have accelerated the pace of innovation, reduced time-to-market for new therapies, and enhanced global R&D infrastructure. As clinical success rates improve and regulatory agencies provide clearer pathways, the market continues to expand. A key trend shaping the landscape is the growing focus on induced pluripotent stem cells (iPSCs), which are transforming personalized medicine by enabling ethically sound, patient-specific treatment options. iPSCs are increasingly utilized for disease modeling, regenerative therapies, and drug discovery, with strong clinical outcomes reinforcing their value.

On the opportunity front, advancements in bioprinting, off-the-shelf allogeneic therapies, and academic-industry collaborations are opening new avenues for scalable and accessible stem cell-based treatments. However, significant restraints persist. Ethical controversies surrounding embryonic stem cells continue to provoke public concern and regulatory hurdles. Recent legal actions against unethical practices have heightened scrutiny. High treatment costs and limited long-term efficacy data for certain applications also slow adoption. Despite these challenges, the market’s future remains promising, fueled by innovation, cross-disciplinary integration, and rising healthcare demand.

Facts & Figures

Extracts Market

• Surge in Research Funding & Grant Support: Significant funding, from public and private sources, is accelerating R&D and clinical progress.
  For instance, in June?2025, Maryland allocated $18 million to human stem cell research, and in March?2025, Canada invested $49.9 million in biomanufacturing infrastructure.
• Technological Advancements in Gene Editing & Cell Engineering: CRISPR, CAR-T/NK, and in vivo engineering are enhancing cell therapy precision and efficacy. Recently, in May?2025, Fred Hutch researchers unveiled a novel method to genetically engineer HSCs in vivo, advancing therapy customization
• Emergence of iPSC-Based Personalized Therapies: iPSCs offer ethical, patient-specific treatment options that mitigate rejection and bypass embryonic controversies.
• Improved Clinical Outcomes & Adoption Rates: Breakthrough trials are boosting confidence and regulatory approval in cell therapy treatments. For instance, in June?13?2025 trial in Australia reduced graft-versus-host disease by 50% in leukaemia patients, tripling disease-free survival post-HSC transplant.
• Rising Burden of Chronic & Degenerative Diseases: Increasing prevalence of conditions like cancer, cardiovascular, and neurodegenerative disorders fuels demand for advanced stem cell therapies

Key Developments

• In May 2025, Cellenkos Inc. partnered with King Faisal Specialist Hospital to run clinical trials in Saudi Arabia using umbilical cord–derived T-reg cells for treating aplastic anemia, ALS, and graft-versus-host disease.
• In March 2025, AstraZeneca is set to acquire EsoBiotec for up to $1?billion, expanding its in vivo immune cell engineering capacity and reinforcing its position in the oncology and autoimmune cell therapy markets.
• In March 2025, Cellino and Matricelf collaborated to drive personalized treatments for spinal cord injury on a worldwide stage. By integrating Cellino’s Nebula™ platform, an AI-powered biomanufacturing platform for iPSCs, with Matricelf’s double autologous methodology for 3D differentiation, the partnership is enabling scalable patient-customized treatments.
• In January 2025, the New York Stem Cell Foundation partnered with Janssen to leverage AI-powered, automated stem cell platforms for drug discovery in neurodegenerative diseases like Parkinson’s and Alzheimer’s.

Stem Cell Therapy Market Segmentation

Based on the cell source

• Adult Stem Cells (ASCs)
• Hematopoietic Stem Cells (HSCs)
• Mesenchymal Stem Cells (MSCs)
• Human Embryonic Stem Cells (HESCs)
• Induced Pluripotent Stem Cells (iPSCs)

The mesenchymal stem cells (MSCs) segment is anticipated to hold the largest share of the market through the forecast period. MSCs with regenerative and immunomodulatory properties are used extensively to cure degenerative diseases, immune-related diseases, and inflammatory diseases. MSCs are capable of differentiating into various cell types, including bone cells, cartilage cells, and fat cells, and are hence of immense application in regenerative medicine. The increasing application of MSCs in orthopaedics, neurology, cardiology, and oncology has fuelled demand for MSCs. Adult Stem Cells (ASCs) and Hematopoietic Stem Cells (HSCs) also contribute significantly, especially in bone marrow transplants. Meanwhile, Human Embryonic Stem Cells (HESCs) and iPSCs, although gaining traction for their pluripotent capabilities, are still limited by ethical concerns and high production costs.

 Based on the type

• Allogeneic Transplants
• Autologous Transplants

The allogeneic stem cell therapy segment is set to dominate this market through the forecast period. This is driven by increasing demand for off-the-shelf stem cell therapy that offers a standardized treatment in comparison to autologous therapy. Allogeneic stem cell therapy employs donor cells and avoids patient-invasive procedures, and guarantees instant availability for serious conditions. The growing prevalence of chronic diseases like blood diseases, immune system disorders, and cancers has been a key factor in driving this sector. Additionally, advances in cell banking, donor compatibility, and immunosuppressive techniques have made allogeneic stem cell therapy safer and more efficient and have driven greater adoption. Meanwhile Autologous Transplant market possesses relatively low market share.

Based on the application

• Musculoskeletal Disorders
• Inflammatory & Autoimmune Disease
• Oncology
• Cardiovascular Diseases
• Wounds and Injuries
• Haematology
• Neurological Disorders
• Other Application

The Musculoskeletal Disorders segment was the highest in the market and is projected to grow with the highest compound annual growth rate (CAGR) during the forecast period. Osteoarthritis, rheumatoid arthritis, and spinal cord injuries are some of the musculoskeletal diseases that are impacting millions of individuals around the world and are causing increasing demand for regenerative medicine. Stem cell therapy is a possible replacement for existing treatments by causing the regeneration of tissues, reducing inflammation, and enhancing mobility. Rising age-related musculoskeletal diseases and sports injuries have been a key factor in driving this segment. Moreover, increased clinical trials and government support for studies on stem cells are fueling the development of innovative treatments.

Based on the end user

• Hospitals & Specialty Clinics
• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes

The clinics segment is projected to grow with the highest compound annual growth rate (CAGR) in the market through the forecast period. Expansion in stem cell treatment adoption in specialist and hospital clinics is driven by rising patient demand for cutting-edge regenerative therapy and improvement in healthcare infrastructure. Hospitals and medical centers are increasingly using stem cell therapy as part of routine medical practice to address diseases such as musculoskeletal disease, cardiovascular disease, neurological disease, and immune system dysfunctions. Specialized equipment and skilled medical personnel make stem cell therapy more effective and are driving the development of this segment. In addition, collaborations between medical providers and biotech firms have given rise to stem cell therapy centers in medical centers.